Xtant Medical Holdings, Inc.

As of May 15, 2024, Xtant Medical Holdings, Inc. is considered a risky investment due to its overvaluation, negative performance metrics, and significant inefficiencies in generating returns, despite a year-to-date stock performance that has outpaced the S&P 500.

As of May 15, 2024, Xtant Medical Holdings, Inc. is considered overvalued and classified as risky due to poor financial ratios and a significant decline in stock performance compared to the S&P 500.

As of June 4, 2025, the trend is mildly bullish due to positive indicators like a bullish MACD and daily moving average, but mixed signals from longer-term indicators suggest caution.

As of March 2022, the management team of Xtant Medical Holdings, Inc. includes Sean Browne (President and CEO), John Bakewell, Michael Eggenberg, Robert McNamara, Jeffrey Peters, and Matthew Rizzo, all serving as directors. They oversee the company's operations and strategic direction.

Xtant Medical Holdings, Inc. develops and markets regenerative medicine products and medical devices in the Pharmaceuticals & Biotechnology sector. As of March 2025, it reported net sales of $33 million and has a market cap of $83.61 million.

As of Jun 18, Xtant Medical Holdings, Inc. has a market capitalization of 83.61 million, with net sales of 122.29 million and a net profit of -11.99 million over the latest four quarters. The company reported shareholder's funds of 42.96 million and total assets of 93.84 million as of Dec 24.